Compare PSNY & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSNY | MRVI |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 2021 | 2020 |
| Metric | PSNY | MRVI |
|---|---|---|
| Price | $6.27 | $7.48 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $12.50 | $7.60 |
| AVG Volume (30 Days) | 291.6K | ★ 2.0M |
| Earning Date | 09-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $185,743,000.00 |
| Revenue This Year | $3.84 | $14.01 |
| Revenue Next Year | $35.40 | $6.09 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.50 | $2.55 |
| 52 Week High | $23.75 | $9.42 |
| Indicator | PSNY | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 20.44 | 55.53 |
| Support Level | N/A | $5.54 |
| Resistance Level | $8.15 | $7.60 |
| Average True Range (ATR) | 0.38 | 0.34 |
| MACD | 0.10 | 0.04 |
| Stochastic Oscillator | 0.81 | 83.01 |
Polestar Automotive Holding UK PLC is a pure play, premium electric car brand, designing performance cars engineered to excite consumers and drive change. It believes that it defines market standards in design, innovation and sustainability. It is determined to improve society by accelerating the shift to sustainable mobility. The company conducts its business as one operating segment with primary commercial operations in Europe, North America, Asia Pacific and various importer markets. The company generates majority of revenue from United Kingdom.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.